`
`UNITED STATES PATENT AND TRADEMARK OFFICE
`_________________________
`
`BEFORE THE PATENT TRIAL AND APPEAL BOARD
`_________________________
`
`SUN PHARMACEUTICAL INDUSTRIES LTD.
`Petitioner,
`v.
`MERCK SHARP & DOHME CORP.
`Patent Owner.
`_________________________
`Case IPR2020-01072
`Patent No. 7,326,708
`_________________________
`
`PETITIONER’S UPDATED EXHIBIT LIST
`
`
`Mail Stop PATENT BOARD
`Patent Trial and Appeal Board
`U.S. Patent and Trademark Office
`P.O. Box 1450
`Alexandria, VA 22313-1450
`Submitted Electronically via the PTAB E2E System
`
`
`
`
`
`Exhibit No.
`1001
`1002
`1003
`1004
`1005
`1006
`
`1007
`1008
`1009
`1010
`
`1011
`1012
`1013
`1014
`1015
`
`1016
`
`1017
`
`1018
`
`1019
`
`1020
`
`Exhibit List
`
`Description
`U.S. Patent No. 7,326,708
`Declaration of Dr. Steven M. Baldwin
`CV of Dr. Steven M. Baldwin
`WO 03/004498 to Edmonson
`Brittain, “Polymorphism in Pharmaceutical Solids”
`Bastin et al. “Salt Selection and Optimisation [sic] Procedures for
`Pharmaceutical New Chemical Entities”
`U.S. Patent No 6,699,871
`Orange Book Entry for Janumet®
`Orange Book Entry for Januvia®
`Complete copy of the prosecution history of the ʼ708 patent as
`available for download from the USPTO website
`U.S. Patent No. 4,572,909
`U.S. Provisional Application No. 60/303,474, filed July 6, 2001
`Prescribing Information for Janumet®
`Prescribing Information for Januvia®
`Merck Sharpe & Dohme’s Responses and Objections to
`Defendants’ First Set of Joint Interrogatories (1-10)
`Brown et al., Chemistry: The Central Science, 8th Revised
`Edition, 615-618 (2002)
`Mylan Pharmaceuticals Inc. v. Merck Sharp & Dohme Corp.,
`IPR2020-00040, Ex. 1002, Declaration of Dr. Mukund
`Chorghade, Ph.D. (Oct. 29, 2019)
`Reserved
`
` Email from Merck to Joinder Petitioners Regarding Silent
` Understudy Conditions
` Complaint, Merck Sharp & Dohme Corp. v. Dr. Reddy’s
` Laboratories, Inc. et al., No. 1:20-cv-00847-RGA, ECF 1 (D. Del.
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`June 24, 2020)
`
`1021
`
`1022
`
` Decision, State of Israel Commissioner of Patents, Designs and
` Trademarks, Teva Pharmaceutical Industries Ltd. Opposition to
` Merck Sharp & Dohme Corp. Patent Application No. 172563
`(July 30, 2019)
` Third Declaration of Leonard J. Chyall, Ph.D
`
`Winston & Strawn LLP
`
`Date: July 29, 2020
`
`/ Jovial Wong /
`
`Jovial Wong (Reg.
`No. 60,115)
`
`Lead Counsel for Petitioner Sun
`Pharmaceutical Industries Ltd.
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`CERTIFICATION OF SERVICE ON PATENT OWNER
`
`Pursuant to 37 C.F.R. §§ 42.6(e), 42.8(b)(4), I certify that I caused to be served
`
`a true and correct copy of the foregoing Petitioner’s Updated Exhibit List
`
`electronically via e-mail on July 29, 2020 on the following counsel of record:
`
`Stanley E. Fisher (sfisher@wc.com)
`Jessamyn S. Berniker (jberniker@wc.com)
`Elise M. Baumgarten (ebaumgarten@wc.com)
`Bruce R. Genderson (bgenderson@wc.com)
`Shaun P. Mahaffy (smahaffy@wc.com)
`Anthony H. Sheh (asheh@wc.com)
`Williams & Connolly LLP
`725 Twelfth Street, N.W.
`Washington, DC 20005
`MerckSitagliptin@wc.com
`
`
`
`Respectfully Submitted,
`
`Winston & Strawn LLP
`
`/ Jovial Wong /
`
`Jovial Wong (Reg.
`No. 60,115)
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`